Fluctuation of the left ventricular ejection fraction in patients with HER2-positive early breast cancer treated by 12 months of adjuvant trastuzumab

Q Jacquinot, S Paget-Bailly, P Fumoleau, G Romieu… - The Breast, 2018 - Elsevier
Background Cardiac toxicity with a decrease of the left ventricular ejection fraction (LVEF) is
the main side effect induced by trastuzumab. This study reports the fluctuation of LVEF over …
被引用次数：9 相关文章

Fluctuation of the left ventricular ejection fraction in patients with HER2-positive early breast cancer treated by 12 months of adjuvant trastuzumab

Q Jacquinot, S Paget-Bailly, P Fumoleau… - The …, 2018 - thebreastonline.com
Background Cardiac toxicity with a decrease of the left ventricular ejection fraction (LVEF) is
the main side effect induced by trastuzumab. This study reports the fluctuation of LVEF over …

Fluctuation of the left ventricular ejection fraction in patients with HER2-positive early breast cancer treated by 12 months of adjuvant trastuzumab

Q Jacquinot, S Paget-Bailly… - Breast (Edinburgh …, 2018 - pubmed.ncbi.nlm.nih.gov
Background Cardiac toxicity with a decrease of the left ventricular ejection fraction (LVEF) is
the main side effect induced by trastuzumab. This study reports the fluctuation of LVEF over …

Fluctuation of the left ventricular ejection fraction in patients with HER2-positive early breast cancer treated by 12 months of adjuvant trastuzumab.

Q Jacquinot, S Paget-Bailly, P Fumoleau… - Breast (Edinburgh …, 2018 - europepmc.org
Background Cardiac toxicity with a decrease of the left ventricular ejection fraction (LVEF) is
the main side effect induced by trastuzumab. This study reports the fluctuation of LVEF over …